News
Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients: Miami Saturday, August 2, 2025, 18:00 Hrs [IST] Pasith ...
US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis: Valencia, California Saturday, August 2, 2025, 17:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback